Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.

Ambre Deniniolle, Maxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Pierre Peterlin, Patrice Chevallier

Blood (2025) 146 (Supplement 1): 7785.

https://doi.org/10.1182/blood-2025-7785

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.

Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Thierry Guillaume, Sophie Vantyghem, Aude-Marie Fourmont, Yannick Le Bris, Olivier Theisen, Marion Eveillard, Maxime Jullien, Alexandra Jobert, Cloe Geay, Joëlle Gaschet, Patrice Chevallier

Blood (2025) 146 (Supplement 1): 5193.

https://doi.org/10.1182/blood-2025-5193

Published: 2025

Journal Articles

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Lionel Ades, Steven Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. Götze, Aristoteles Giagounidis, Deepak Singhal, Dominic Brauer, Carolyn Grove, Katharina Mohr, Fatiha Chermat, Joanna Nkyekyer, Uwe Platzbecker

Blood (2025) 146 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2025-5155

Published: 2025

Journal Articles

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Blood (2025) 146 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2025-5247

Published: 2025

Journal Articles

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Vincent Jachiet, Olivier Kosmider, Maxime Beydon, Jérôme Hadjadj, Lin-Pierre Zhao, Vincent Grobost, Valentin Lacombe, Guillaume Le Guenno, Yann Nguyen, Jean-Benoît Arlet, Jérémie Dion, Maël Heiblig, Alice Garnier, Maxime Samson, Achille Aouba, Sylvain Thépot, Sophie Dimicoli-Salazar, Fabien Dutasta, Benoît Faucher, Estibaliz Lazaro, Véronique Morel, Antoine Néel, Roderau Outh, Holy Bezanahary, Julien Rossignol, Anne-Sophie Alary, Audrey Bidet, Pauline Blateau, Anne Bouvier, Guilaine Boursier, Matthieu Decamp, Benjamin Lebecque, Yannick Le Bris, Pierre Sujobert, Alice Marceau-Renaut, Cédric Pastoret, David Rizzo, Nathalie Boiret-Dupré, Lara Boucher, Stéphanie Dulucq, Franck Genevieve, Cassandra Jadeau, Pierre Lemaire, Romain Vazquez, Jean-Baptiste Rieu, Olivier Fain, Sophie Georgin-Lavialle, Lucie Rigolot, Lise Larcher, Pierre Hirsch, Benjamin Terrier, Pierre Fenaux, Arsène Mékinian, Thibault Comont

Blood (2025) 146 (12): 1450–1461.

https://doi.org/10.1182/blood.2024028133

Published: 2025

Includes: Supplemental data

Journal Articles

Chronic Myelomonocytic Leukemia Associated Adult Langerhans Cell Histiocytosis: A Descriptive and Comparative Study

Eva Chauvel, Jean-François Emile, Alice Garnier, Simon Bouzy, Sebastien Barbarot, Eric Lagrue, Antoine Neel

Blood (2024) 144 (Supplement 1): 6733.

https://doi.org/10.1182/blood-2024-200371

Published: 2024

Journal Articles

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

Valentin Letailleur, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 3506.

https://doi.org/10.1182/blood-2024-203972

Published: 2024

Journal Articles

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Uwe Platzbecker, Steven W Lane, Alice Garnier, Thomas Cluzeau, Odile Rauzy, Katharina S. S. Götze, Aristoteles Giagounidis, Deepak Singhal, Aicha Kopecky, Fatiha Chermat, Lionel Ades

Blood (2024) 144 (Supplement 1): 3222.

https://doi.org/10.1182/blood-2024-194185

Published: 2024

Journal Articles

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Laura Prin Felix, Maxime Jullien, Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Sophie Vantyghem, Aude-Marie Fourmont, Thierry Guillaume, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 4882.

https://doi.org/10.1182/blood-2024-203266

Published: 2024

Journal Articles

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Maxime Jullien, Catherine Willem, Perla Salameh, Enora Ferron, Alice Garnier, Pierre Peterlin, Amandine Le Bourgeois, Thierry Guillaume, Katia Gagne, Patrice Chevallier, Christelle Retiere

Blood (2024) 144 (Supplement 1): 2137.

https://doi.org/10.1182/blood-2024-202902

Published: 2024

Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Blood (2024) 144 (Supplement 1): 353.

https://doi.org/10.1182/blood-2024-198326

Published: 2024

Journal Articles

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Lionel Ades, Thomas Cluzeau, Thibault Comont, Lorea Aguinaga, Aspasia Stamatoullas, Mathieu Meunier, Emmanuel Gyan, Alice Garnier, Maud D'Aveni, Sylvain Thépot, Marie Sebert, Marius Moldovan, Anouk Walter Petrich, Karine Lemarie, Fatiha Chermat, Michaela Fontenay, Sylvie Chevret, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 351.

https://doi.org/10.1182/blood-2024-204791

Published: 2024

Journal Articles

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Blood (2024) 144 (Supplement 1): 349.

https://doi.org/10.1182/blood-2024-194510

Published: 2024

Journal Articles

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Mathilde Bastien, Maxime Jullien, Nicolas Vallet, Aline Schmidt, Tony Marchand, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Corentin Orvain, Marc Bernard, Thierry Guillaume, Jean-Baptiste Méar, Mathilde Hunault, Emmanuel Gyan, Pierre Peterlin, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2024-201589

Published: 2024

Journal Articles

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Flore Sicre de Fontbrune, Edouard Forcade, Louis Terriou, Alice Garnier, Vincent Alcazer, Nicolas Daguindau, Lynda Maafa, Isabelle Brindel, Regis Peffault de Latour, Sylvie Chevret

Blood (2024) 144 (Supplement 1): 1321.

https://doi.org/10.1182/blood-2024-199472

Published: 2024

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

Amandine Le Bourgeois, Alice Garnier, Pierre Peterlin, Maxime Jullien, Chloe Antier, Thierry Guillaume, Patrice Chevallier

Blood (2023) 142 (Supplement 1): 6963.

https://doi.org/10.1182/blood-2023-179861

Published: 2023

Journal Articles

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

Patrice Chevallier, Anne Thiebaut, Sylvie François, Sylvain Chantepie, Marie Thérèse Rubio, Hélène Labussière-Wallet, Eolia Brissot, Natacha Maillard, Anne Huynh, Valerie Coiteux, Alice Garnier, Amandine Le Bourgeois, Pierre Peterlin, Thierry Guillaume

Blood (2023) 142 (Supplement 1): 4957.

https://doi.org/10.1182/blood-2023-179734

Published: 2023

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

First-in-human trial of siltuximab in combination with standard induction chemotherapy in patients with acute myeloid leukemia: The Phase 1 siltuxilam study.

A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study

Validation of the FL/IL6 score, a new dynamic cytokine-based risk-model in adults with acute myeloid leukemia, a prospective multicentre filo study.

Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX

Chronic Myelomonocytic Leukemia Associated Adult Langerhans Cell Histiocytosis: A Descriptive and Comparative Study

Letermovir Provides Protection Against Clinically Significant CMV Infections in CMV-Seronegative Recipients of an Allotransplant from a CMV-Seropositive Donor

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study

Treosulfan Vs Busulfan As Part of Clofarabine Based Reduced Intensity Conditioning Regimen before Allotransplant for Myeloid Malignancies

Reconstitution and Licensing of Natural Killer Cells Following T-Cell Replete Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide and Antithymocyte Globulin

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study

Early Versus Late Onset of ESA in Lower Risk Anemic MDS Patients: Results of the GFM Randomized Phase III EPO-Pretar Trial

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Efficacy and Safety of Pegcetacoplan in PNH Patients with Extra-Vascular Hemolysis Under Anti-C5: The Real-Life Experience of the National French Reference Center

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study

A Phase 2 Study of Ponatinib for Prevention of Relapse after Allotransplantation in FLT3-ITD + AML Patients : The Ponallo Trial

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only